

# [FDA approves Tecentriq combo for NSCLC](#)

written by CAP TODAY

February 19, 2020

February 2020—Roche announced FDA approval of Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer with no *EGFR* or *ALK* genomic tumor aberrations. The European Commission approved the combination therapy in September.

[Roche](#), 317-521-2000



©2026 CAP TODAY, all rights reserved.